Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid tumors (ACTengine IMA201-101)
TCR-engineered T Cells in Solid Tumors With Focus on Non-small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: Immatics
Enrolling: Male and Female Patients
IRB Number: AAAS6577
U.S. Govt. ID: NCT03247309
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The goal of the study is to learn if it is safe to give genetically changed T cells (IMA201) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of IMA201 and if the study drug can help to control the disease. Cancers include: Breast cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancers, liver cancer, lung cancer, skin cancer, and pancreatic cancer.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have recurrent or refractory solid tumors, including non-small cell lung cancer or head and neck squamous cell carcinoma? Yes No
Are you willing to undergo testing, such as biopsies and blood draws? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE